Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated Type 2 diabetic patients

Diabetes Research and Clinical Practice

Volumn 98, Issue 1, 2012, Pages 119-124

  Ragia, Georgia ^a   Tavridou, Anna ^a   Petridis, Ioannis ^a,b   Manolopoulos, Vangelis G ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Academic General Hospital Alexandroupolis   (Greece)

Author keywords

E23K polymorphism; Hypoglycemia; KCNJ11; Kir6.2; Pharmacogenetics; Sulfonylureas; Type 2 diabetes

Indexed keywords

GLICLAZIDE; GLIMEPIRIDE; SULFONYLUREA;

ADULT; AGE; AGED; ALLELE; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DNA POLYMORPHISM; DOSE RESPONSE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPOGLYCEMIA; INCIDENCE; KCNJ11 E23K GENE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; GLICLAZIDE; GLUTAMIC ACID; GREECE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; LYSINE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POTASSIUM CHANNELS, INWARDLY RECTIFYING; SULFONYLUREA COMPOUNDS;

EID: 84867404207     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.04.017     Document Type: Article

References (34)

1. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004, 64:1339-1358.
2. Melander A. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview. Diabetes 2004, 53(Suppl. 3):S151-S155.
3. Krentz A.J., Bailey C.J. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005, 65:385-411.
4. Pearson E.R. Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes. Front Biosci 2009, 14:4348-4362.
5. Manolopoulos V.G., Ragia G., Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 2011, 12:1161-1191.
6. Chao J., Nau D.P., Aikens J.E. Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus. Clin Ther 2007, 29:177-180.
7. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
8. Florez J.C., Burtt N., de Bakker P.I., Almgren P., Tuomi T., Holmkvist J., et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 2004, 53:1360-1368.
9. Haider S., Antcliff J.F., Proks P., Sansom M.S., Ashcroft F.M. Focus on Kir6.2: a key component of the ATP-sensitive potassium channel. J Mol Cell Cardiol 2005, 38:927-936.
10. Pearson E.R., Flechtner I., Njolstad P.R., Malecki M.T., Flanagan S.E., Larkin B., et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006, 355:467-477.
11. Meirhaeghe A., Helbecque N., Cottel D., Arveiler D., Ruidavets J.B., Haas B., et al. Impact of sulfonylurea receptor 1 genetic variability on non-insulin-dependent diabetes mellitus prevalence and treatment: a population study. Am J Med Genet 2001, 101:4-8.
12. Feng Y., Mao G., Ren X., Xing H., Tang G., Li Q., et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 2008, 31:1939-1944.
13. Gloyn A.L., Weedon M.N., Owen K.R., Turner M.J., Knight B.A., Hitman G., et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003, 52:568-572.
14. Holstein A., Hahn M., Stumvoll M., Kovacs P. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res 2009, 41:387-390.
15. Ragia G., Petridis I., Tavridou A., Christakidis D., Manolopoulos V.G. Presence of CYP2C93 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 2009, 10:1781-1787.
16. Iordanidou M., Tavridou A., Petridis I., Kyroglou S., Kaklamanis L., Christakidis D., et al. Association of polymorphisms of the serotonergic system with smoking initiation in Caucasians. Drug Alcohol Depend 2010, 108:70-76.
17. Iordanidou M., Tavridou A., Vasiliadis M.V., Arvanitidis K.I., Petridis J., Christakidis D., et al. The -759C/T polymorphism of the 5-HT2C receptor is associated with type 2 diabetes in male and female Caucasians. Pharmacogenet Genomics 2008, 18:153-159.
18. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005, 28:1245-1249.
19. He Y.Y., Zhang R., Shao X.Y., Hu C., Wang C.R., Lu J.X., et al. Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. Acta Pharmacol Sin 2008, 29:983-989.
20. Burge M.R., Schmitz-Fiorentino K., Fischette C., Qualls C.R., Schade D.S. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA 1998, 279:137-143.
21. Zammitt N.N., Frier B.M. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005, 28:2948-2961.
22. Leese G.P., Wang J., Broomhall J., Kelly P., Marsden A., Morrison W., et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003, 26:1176-1180.
23. Gabriely I., Shamoon H. Hypoglycemia in diabetes: common, often unrecognized. Cleve Clin J Med 2004, 71:335-342.
24. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007, 50:1140-1147.
25. Miller C.D., Phillips L.S., Ziemer D.C., Gallina D.L., Cook C.B., El-Kebbi I.M. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001, 161:1653-1659.
26. Holstein A., Plaschke A., Ptak M., Egberts E.H., El-Din J., Brockmoller J., et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 2005, 60:103-106.
27. Gokalp O., Gunes A., Cam H., Cure E., Aydin O., Tamer M.N., et al. Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. Eur J Clin Pharmacol 2011, 67:1223-1229.
28. Freitas A.I., Mendonca I., Brion M., Sequeira M.M., Reis R.P., Carracedo A., et al. RAS gene polymorphisms, classical risk factors and the advent of coronary artery disease in the Portuguese population. BMC Cardiovasc Disord 2008, 8:15.
29. Roncaglioni M.C., Santoro L., D'Avanzo B., Negri E., Nobili A., Ledda A., et al. Role of family history in patients with myocardial infarction. An Italian case-control study, GISSI-EFRIM Investigators. Circulation 1992, 85:2065-2072.
30. Barroso I., Luan J., Middelberg R.P., Harding A.H., Franks P.W., Jakes R.W., et al. Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action. PLoS Biol 2003, 1:E20.
31. Chistiakov D.A., Potapov V.A., Khodirev D.C., Shamkhalova M.S., Shestakova M.V., Nosikov V.V. Genetic variations in the pancreatic ATP-sensitive potassium channel, beta-cell dysfunction, and susceptibility to type 2 diabetes. Acta Diabetol 2009, 46:43-49.
32. van Dam R.M., Hoebee B., Seidell J.C., Schaap M.M., de Bruin T.W., Feskens E.J. Common variants in the ATP-sensitive K+ channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance: population-based studies and meta-analyses. Diabet Med 2005, 22:590-598.
33. Rafiq M., Flanagan S.E., Patch A.M., Shields B.M., Ellard S., Hattersley A.T. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 2008, 31:204-209.
34. Zhang H., Liu X., Kuang H., Yi R., Xing H. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Res Clin Pract 2007, 77:58-61.